A Study to Evaluate the Immune Response of Healthy Individuals for the 2017-2018 Seasonal Flu Vaccine

Overview

Información sobre este estudio

The purpose of this study is to evaluate the immune response of healthy individuals to the 2017-2018 seasonal flu vaccine.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Subject is 19 - 79 years of age.
  • Willingness and ability to provide informed consent.
  • Subject is able to participate fully in all aspects of the study.
  • Generally healthly, as determined by study investigators, and not meeting any of the exclusion criteria listed below.
  • Is eligible for the 2017-2018 and/or 2018-2019 seasonal influenza vaccine.

Exclusion Criteria: 

  • Subject has received this year’s influenza vaccine (2017-2018 or 2018-2019 season; as relevant to each particular season) outside of this study.
  • Subject has a history of severe adverse reaction associated with an influenza vaccine.
  • Subject is allergic to egg proteins and chicken proteins.
  • Subject has a history of Guillain-Barre syndrome.
  • Subject has a known or suspected immunodeficiency.
  • Subject is on a medication that directly affects the outcome, i.e., treatment with immunosuppressive therapy including:
    • cytotoxic agents or systemic corticosteroids,  systemic corticosteroids for treatment of an acute illness in the last 30 days;
    • a blood product (including immunoglobulin) within 6 months prior to enrollment in the study;
    • anticoagulant therapy (not including anti-platelet drugs such as aspirin and clopidogrel) that would contraindicate intramuscular injection.
  • Subject has had a recent (within 6 months) myocardial infarction, fracture, cancer or unplanned hospitalisation.
  • Subject weighs ≤ 110 lbs.
  • Subject has donated blood in the past 56 days or plans to donate blood at time of study or within 8 weeks after their participation in the study ends weeks after their participation in the study ends.
  • Pregnancy (as determined by history or self-report).
  • Trying to conceive at time of study or for 28 days after vaccination.
  • Transgender women/men will be excluded due to the potential effect of this status on the immune response.
  • Note that individuals with stable chronic disease (HTN that is well controlled, T2DM with A1C < 8, CHF if NYHA class I or II) can be included.

 

 

 

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Amir Sadighi Akha, M.D., D.Phil.

Cerrado para la inscripción

Contact information:

Lisa Hines

(507)266-1710

Hines.Lisa@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20357698

Mayo Clinic Footer